Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069445 | 0.92 | SMN1; SMN2 (0.74) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL21070677 | 0.92 | SMN1; SMN2 (0.74) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL6758924 | 0.92 | SMN1; SMN2 (0.74) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL21069451 | 0.92 | SMN1; SMN2 (0.74) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL3445880 | 0.92 | HTT (0.62) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL2453446 | 0.91 | HTT (0.60) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL10954785 | 0.89 | TGM2 (0.60) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL23539446 | 0.86 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL19343344 | 0.86 | LMNA (0.68) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL13035566 | 0.85 | LMNA (0.55) | LMNASMN1; SMN2L3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4440701-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3483166-B1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA INST SCI & TECH (KR) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-08-25 | — | — | US | disclosed |
| US-6689800-B2 | β3-adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof | PFIZER INC. | 2004-02-10 | — | — | US | disclosed |
| US-6689888-B2 | Processes and intermediates useful in preparing β3-adrenergic receptor agonists | PFIZER INC. | 2004-02-10 | — | — | US | disclosed |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030199046-A1 | Processes and intermediates useful in preparing beta3-adrenergic receptor agonists | CHAMBERS ROBERT J (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030199556-A1 | beta3- adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030166686-A1 | Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2003072572-A1 | BETA3-ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072571-A1 | SALT OF A PYRIDYL ETHANOLAMINE DERIVATIVE AND ITS USE AS A BETA-3-ADRENERGIC RECEPTOR AGONIST | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072547-A1 | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072573-A1 | CRYSTAL FORMS OF (R)-2-(2-(4-OXAZOL-4-YL-PHENOXY)-ETHYLAMINO)-1-PYRIDIN-3-YL-ETHANOL | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885SMN1; SMN2 2647/4885L3MBTL1 1394/4885 |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | LMNA 1304/4885SMN1; SMN2 1782/4885L3MBTL1 2895/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885SMN1; SMN2 2647/4885L3MBTL1 1394/4885 |
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | IL1B, IL1A, CASP1 | LMNA 2527/4885SMN1; SMN2 2514/4885L3MBTL1 4200/4885 |
| US-20030199046-A1 | Processes and intermediates useful in preparing beta3-adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | LMNA 1771/4885SMN1; SMN2 4220/4885L3MBTL1 4866/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885SMN1; SMN2 2647/4885L3MBTL1 1394/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885SMN1; SMN2 2647/4885L3MBTL1 1394/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885SMN1; SMN2 2647/4885L3MBTL1 1394/4885 |
| US-20030199556-A1 | beta3- adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof | ADRB3, ADRB1, ADRB2 | LMNA 503/4885SMN1; SMN2 1499/4885L3MBTL1 1685/4885 |
| US-20030166686-A1 | Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof | ADRB3, ADRB1, ADRB2 | LMNA 642/4885SMN1; SMN2 1556/4885L3MBTL1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.